ECKERT & ZIEGLER BG 
By Berlin, 24 August 2011; Prostate cancer is the second most frequent type of cancer in men and is affecting younger and younger patients. If prostate cancer is detected in good time, it can often be treated effectively and gently, without impairing the patient's quality of life. This is why it is important that patients should be informed about the early symptoms and how this carcinoma can be detected at an early stage, together with adequate details of treatment options.
Eckert & Ziegler BEBIG have issued a new information brochure about prostate cancer.The brochure is available in German and English and provides detailed information about prostate cancer, with clear information about the various methods of early detection and treatment.
The brochure can be ordered free of charge from:
Eckert & Ziegler BEBIG GmbH
Reference: "Patient Brochure"
Robert-Rössle-Str. 10
13125 Berlin
Tel.: 030941084272
Fax: 030941084410
Mail: dorota.tkaczyk@bebig.eu:
mailto:dorota.tkaczyk@bebig.eu
Download:
http://www.bebig.eu/fileadmin/ibt-bebig.eu/fileadmin/pdf/PatientBrochure_English.pdf:
http://www.bebig.eu/fileadmin/ibt-bebig.eu/fileadmin/pdf/PatientBrochure_English.pdf
The brochure tells patients how prostate cancer can be detected at an early stage and which therapies can then be used. Locally restricted prostate cancer can be treated in several different ways, which have similar efficacy. One particularly effective way is to use so-called LDR brachytherapy with extremely small weakly radioactive implants. Tiny iodine-125 capsules (known as "seeds") are placed in specific positions in the prostate, ensuring that the dose is optimally distributed within the target tissue, without exposing the surrounding organs. Moreover, LDR brachytherapy is highly effective and well tolerated. The treatment period is short and the patient recovers relatively quickly.
LDR brachytherapy may be performed with products from Eckert & Ziegler BEBIG, including IsoSeed® (individual seeds) or IsoCord® (seed chains). These have been successfully used for more than ten years in clinical practice.
About Eckert & Ziegler BEBIG
Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry.
Eckert & Ziegler BEBIG's core business is the treatment of cancer using brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe and in India. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing of its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. The company has been listed on the Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB).
Contact
Paul-Emmanuel Goethals
Investor Relations
Tel.: +32.64.520.808
Email: ir@bebig.eu:
mailto:ir@bebig.eu
Website: www.bebig.eu:
http://www.bebig.eu/
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
